gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Melanoma antigen family C, 1

This gene is a member of the melanoma antigen gene (MAGE) family. The proteins of this family are tumor-specific antigens that can be recognized by autologous cytolytic T lymphocytes. This protein contains a large number of unique short repetitive sequences in front of the MAGE-homologous sequence, and therefore is about 800 aa longer than the other MAGE proteins. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: NY-ESO-1, CT10, SSX2, HAD, CAN
Papers on CT7
The expression of MAGE-C1 and MAGE-C2 in breast cancer and their clinical significance.
Shan et al., Shijiazhuang, China. In Am J Surg, Jan 2016
BACKGROUND: Our study aims to analyze the expression pattern, mechanism, and prognostic significance of melanoma-associated antigen MAGE-C1 and MAGE-C2 in breast cancer.
Chromosomal aberrations of cancer-testis antigens in myeloma patients.
Tinguely et al., Zürich, Switzerland. In Hematol Oncol, Sep 2015
MAGE-C1 and MAGE-C2 are two CTAgs located at the Xq27 region of chromosome X and frequently expressed in multiple myeloma.
Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area.
Kwekkeboom et al., Rotterdam, Netherlands. In Br J Cancer, Jul 2015
Expression of a comprehensive panel of cancer-testis (MAGE-A1, MAGE-A3/4, MAGE-A10, MAGE-C1, MAGE-C2, NY-ESO-1, SSX-2, sperm protein 17), onco-fetal (AFP, Glypican-3) and overexpressed tumour antigens (Annexin-A2, Wilms tumor-1, Survivin, Midkine, MUC-1) was determined by immunohistochemistry. RESULTS: A higher prevalence of MAGE antigens was observed in patients with hepatitis-B.
The effect of high-intensity circuit training on physical fitness.
Strutz et al., Oshkosh, United States. In J Sports Med Phys Fitness, Jun 2015
Following baseline testing for height and weight, body composition, aerobic fitness, muscle strength and muscle endurance, subjects were randomly assigned to one of three groups: 7-minute circuit training (CT-7), 14-minute circuit training (CT-14), and a non-training control group (C).
Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma.
Fitsche et al., Zürich, Switzerland. In Biomed Res Int, 2014
As CT7 and CT10 are highly expressed in cutaneous melanoma and are immunogenic in this disease, we analysed their expression throughout the different subtypes of mucosal melanoma and tumor development.
Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.
Koehne et al., New York City, United States. In Cancer Immunol Res, 2014
Cancer-testis antigen 7 (CT7) is the most frequently and consistently expressed MAGE antigen in multiple myeloma, exhibits tissue-restricted expression, and is an independent negative prognostic factor for multiple myeloma.
Cancer-testis antigen expression in digestive tract carcinomas: frequent expression in esophageal squamous cell carcinoma and its precursor lesions.
Yantiss et al., New York City, United States. In Cancer Immunol Res, 2014
The protein expression of eight cancer-testis antigens [MAGEA, NY-ESO-1, GAGE, MAGEC1 (CT7), MAGEC2 (CT10), CT45, SAGE1, and NXF2] was evaluated by immunohistochemistry in 61 esophageal carcinomas (40 adenocarcinoma and 21 squamous cell carcinoma), 50 gastric carcinomas (34 diffuse and 16 intestinal type), and 141 colorectal carcinomas.
Expression of cancer-testis antigen in multiple myeloma.
Ma et al., Wuhan, China. In J Huazhong Univ Sci Technolog Med Sci, 2014
Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to detect the mRNA expression of MAGE-C1/CT7, SSX1, SSX2 and SSX4 in MM cell lines of RPMI-8226 and U266, and bone marrow (BM) cells of 25 MM patients and 18 healthy volunteers.
Impact of different beam directions on intensity-modulated radiation therapy dose delivered to functioning lung tissue identified using single-photon emission computed tomography.
Qu et al., Jinan, China. In Contemp Oncol (pozn), 2013
Four different plans, including CT-7, SPECT-7, SPECT-4, SPECT-5 with different beam arrangements, were used.
Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer.
Odunsi et al., New York City, United States. In Plos One, 2013
mRNA or protein expression frequencies were determined for MAGE-A1, -A3, -A4, -A10 and -C1 (CT7) in tissue samples obtained from 400 patients with EOC.
Is there any relationship between gene expression of tumor antigens and CD4+ T cells in multiple myeloma?
Colleoni et al., São Paulo, Brazil. In Immunotherapy, 2013
MATERIALS & METHODS: MAGE-C1/CT-7, MAGEA3/6, NY-ESO-1, LAGE-1 and GAGE expression were evaluated in 46 bone marrow multiple myeloma (MM) aspirates by RT-PCR.
Monoclonal Antibodies Specific for STAT3β Reveal Its Contribution to Constitutive STAT3 Phosphorylation in Breast Cancer.
Tweardy et al., Houston, United States. In Cancers (basel), 2013
We developed monoclonal antibodies that recognize the 7 C-terminal amino acids unique to Stat3β (CT7) and do not cross-react with Stat3α.
Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy.
Colleoni et al., Botucatu, Brazil. In Clin Dev Immunol, 2011
Among CTAs expressed in MM we must highlight the MAGE-C1/CT7 located on the X chromosome and expressed specificity in the malignant plasma cells.
Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients.
Moch et al., Zürich, Switzerland. In Plos One, 2010
Results suggest that the expression of MAGE-C1/CT7 and MAGE-C2/CT10 in primary melanoma is a potent predictor of sentinel lymph node metastasis.
NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene.
Schleutker et al., Tampere, Finland. In Bmc Cancer, 2010
Data with miRNA target analysis showed that 12 of them had possible target sites in the MAGEC1 gene.
Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
Colleoni et al., São Paulo, Brazil. In Plos One, 2010
the role of MAGE-C1/CT7 in the control of cellular proliferation and cell cycle in myeloma
Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.
Marx et al., Hamburg, Germany. In Exp Mol Pathol, 2010
a content of >/=50% MAGE-C1/CT7 expressing myeloma cells in a sample was associated with reduced overall survival (p=0.013).
Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.
van den Broek et al., Zürich, Switzerland. In Proc Natl Acad Sci U S A, 2010
Peripheral blood mononuclear cells from 26 metastatic melanoma patients expressing CT7 in their tumor lesions were analyzed for CT7-specific T-cell responses using overlapping peptides.
Cancer/testis antigens: structural and immunobiological properties.
Zeuthen et al., In Cancer Invest, 2001
The MAGE superfamily includes five families: MAGE-A, MAGE-B, MAGE-C, MAGE-D, and necdin.
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.
Shoenfeld et al., Beersheba, Israel. In Ann Rheum Dis, 2001
RESULTS: Patients with malignant diseases may develop autoimmune phenomena and rheumatic diseases as a result of (a) generation of autoantibodies against various autoantigens, including oncoproteins (P185, 1-myc, c-myc, c-myb), tumour suppression genes (P53), proliferation associated antigens (cyclin A, B1, D1, E; CENP-F; CDK, U3-RNP), onconeural antigens (Hu, Yo, Ri, Tr), cancer/testis antigens (MAGE, GAGE, BAGE, SSX, ESO, SCP, CT7), and rheumatic disease associated antigens (RNP, Sm).
share on facebooktweetadd +1mail to friends